A novel approach of using a DNA therapeutic platform with a Lipid Nanoparticle (LNP)-based delivery system and focused on veterinary vaccine applications has been evaluated and our preliminary results are reported in this white paper. The studies shown herein support the advancement of high-fidelity, PCR-produced linearDNA™ in vaccine applications, taking advantage of linearDNA’s rapid design, ease of manufacture and thermostability.